The Canada Periodontal Therapeutics Market was valued at $69.8 Mn in 2023 and is predicted to grow at a CAGR of 7.2% from 2023 to 2030, to $113.6 Mn by 2030. Canada Periodontal Therapeutics Market is growing due to Prevalence of periodontitis, Rise in Demand for Non-surgical Periodontal Therapies, and Emphasis on Preventive Oral Care. The market is primarily dominated by players such as Pfizer Inc., Lupin Ltd, Teva Pharmaceuticals USA, Sun Pharmaceutical Industries Ltd, Tokyo Chemical Industry Co. Ltd., and Bausch Health Companies Inc.
The Canada Radiology Service Market was valued at $320 Mn in 2023 and is predicted to grow at a CAGR of 14.7% from 2023 to 2030, to $835.8 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, aging population, and technological advancements. The prominent players of the Canada Radiology Service Market are The Ottawa Hospital, Vancouver General Hospital, St. Paul’s Hospital, Royal Alexandra Hospital, Foothills Medical Centre, and McGill University Health Centre, among others.
The Canada Bone Disease Therapeutics Market was valued at $1.296 Bn in 2022 and is predicted to grow at a CAGR of 8.9% from 2023 to 2030, to $2.563 Bn by 2030. The key drivers of this industry include the increasing aging population of Canada, improving government initiatives, technological advancements, and others. The industry is primarily dominated by players such as Roche, Pfizer, Merck, AbbVie, Novartis, Teva, and Johnson & Johnson, among others.
The Canada MRI Market was valued at $531.20 Mn in 2023 and is predicted to grow at a CAGR of 6.5% from 2023 to 2030, to $825.48 Mn by 2030. The key drivers of this industry include rising prevalence of chronic diseases, technological advancements, and increasing government expenditure. The key players in the industry are Siemens Healthineers, Neusoft, Hitachi High-Tech Corporation, and GE Healthcare among others.
Canada Dental Implant Market was valued at $399.20 Mn in 2023 and is predicted to grow at a CAGR of 9.8% from 2023 to 2030, to $768.10 Mn by 2030. The key drivers of this industry include like growing demand for aesthetics, growing dental awareness, a growing aging population, and improved dental infrastructure. The industry is primarily dominated by Straumann Group, Dentsply Sirona, Zimmer Biomet Ltd, and Henry Schein Holdings Ltd among others.
Canada Genomic Diagnostics Market was valued at $2,612 Mn in 2023 and is predicted to grow at a CAGR of 16.5% from 2023 to 2030, to $7,607.72 Mn by 2030. The key drivers of this industry include early disease detection, personalized medicine, and government funding. The industry is primarily dominated by Illumina, 23andMe, Myriad Genetics, and Amgen among others.
Canada Ear Infection Therapeutics Market valued at $944 Mn in 2022, is projected to reach $1416 Mn by 2030 with a 5.2% CAGR. The rising prevalence of ear infections, particularly in children, is a key driver for the growth of the ear infection therapeutics market, as the increased incidence fosters a demand for effective solutions, propelling research, development, and market availability of treatments to address this widespread medical condition. Key players in this industry include Novartis, AstraZeneca, Cipla, Torrent Pharmaceuticals, Wraser Pharmaceuticals, Glenmark, Sun Pharmaceutical, Candela Healthcare, Torque Pharmaceuticals, and Dr Reddy's Laboratories.
Canada Compression Therapy Market was valued at $304 Mn in 2022 and is estimated to reach $470 Mn in 2030, exhibiting a CAGR of 5.6% during the forecast period. The rising prevalence of venous disorders, including leg ulcers, deep vein thrombosis, lymphedema, varicose veins, and blood clots, serves as a significant growth driver for the compression therapy market. Key players in this industry comprise Bauerfeind, Jobst, Medi, Sigvaris, Juzo, LympheDiv, Gibaud, Varisport, CEP, and McDavid.
The Canada Exosome Research Market was valued at $13.5 Mn in 2023 and is projected to grow at a CAGR of 16% from 2023 to 2023, to $38.2 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Thermo Fisher Scientific, Bio-Techne Crop, QIAGEN, Beckam Coulter, Lonza among others.
Canada CT Scan market was valued at $368.8 Mn in 2023 and is predicted to grow at a CAGR of 7.87% from 2023 to 2030, to $626.75 Mn by 2030. The key drivers of this industry include the aging population, increasing cancer rates, and technological advancement. The industry is primarily dominated by GE HealthCare, Siemens Healthineers, Canon Medical Systems, and NeuroLogica Corp. among others.
The Canada Cough Hypersensitivity Syndrome Therapeutics Market was valued at $0.648 Bn in 2022 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030, to $1.025 Bn by 2030. The key drivers of this industry include the increasing prevalence of Cough Hypersensitivity Syndrome, growing awareness and diagnosis, and the emergence of advanced therapeutics in the industry. The industry is primarily dominated by players such as Teva, Pfizer, Novartis, Johnson & Johnson, and GSK among others.
The Canada Herbal Supplements Market was valued at $420.80 Mn in 2023 and is predicted to grow at a CAGR of 6.2% from 2023 to 2030, to $641.13 Mn by 2030. The key drivers of this industry include growing health awareness, preference for natural products, and aging population. The industry is primarily dominated by players such as Nature’s Way, New Chapter, New Roots Herbal, Botanica Health, and Herbalife among others.
Canada Brain Cancer Therapeutics Market valued at $184 Mn in 2022, projected to reach $1412 Mn by 2030 with a 10.6% CAGR. A significant rise in the occurrence of brain cancer, specifically glioblastoma multiforme, is expected to drive the demand for treatments in the brain cancer therapeutics market. The leading pharmaceutical companies currently operating in the industry are Roche, Novartis, Merck, Pfizer, BMS, Bayer, Celgene, AbbVie, Teva Pharmaceuticals, and Spectrum Pharmaceuticals.
The Canada Brugada Syndrome Market was valued at $96 Mn in 2023 and is predicted to grow at a CAGR of 7.8% from 2023 to 2030, to $162.4 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. The prominent players of the Canada Brugada Syndrome Market are GeneDX, Abbott, PGxHealth LLC, Medtronic, and GE Healthcare, among others.
Canada Clinical Nutrition for Chronic Kidney Diseases Market was valued at $125.60 Mn in 2023 and is predicted to grow at a CAGR of 6.03% from 2023 to 2030, to $189.20 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, growing awareness and diagnosis, advancements in medical research, and the aging population. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
The Canada Adult Glioma Therapeutics Market is valued at around $176 Mn in 2022 and is projected to reach $348 Mn by 2030, exhibiting a CAGR of 8.9% during the forecast period. The market is being driven by increased research and development funding, significant government investments in cancer research, owing to the increased prevalence of brain cancers, the presence of unmet healthcare needs, and a favourable regulatory environment that allows for the rapid approval of innovative medicines. Key players in the Canada Adult Malignant Glioma Therapeutics Market include Roche, Merck & Co., Pfizer, Amgen, Arbor Pharmaceuticals, Karyopharm Therapeutics, Azurity Pharmaceuticals. Medicago Inc., CogniMed Therapeutics, Inc., and others
Canada Blood Disorder Therapeutics Market valued at $1.072 Bn in 2022, projected to reach $1.912 Bn by 2030 with a 7.5% CAGR. The growing adoption of advanced therapies supported by government initiatives, and the rising prevalence of blood disorders, particularly among Canada's aging population, are the main factors driving the market for blood disorder treatment. The Canada Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda Pharmaceutical, Sanofi, Novo Nordisk, Pfizer, Apotex, Paladin Labs, Sandoz, Spark Therapeutics, Bluebird bio, BioMarin Pharmaceuticals etc, among various others.
Canada Dental Endodontics Market was valued at $140 Mn in 2023 and is predicted to grow at a CAGR of 4.3% from 2023 to 2030, to $188 Mn by 2030. The key drivers of this industry include the growing demand for cosmetic dentistry, Technological Advancements, the rising prevalence of dental problems, and the aging population. The industry is primarily dominated by Coltene, Dentsply Sirona, FKG Dentaire, and Ultradent Products among others.
Canada Digital Biomarkers Market was valued at $232 Mn in 2023 and is predicted to grow at a CAGR of 22.3% from 2023 to 2030, to $949.45 Mn by 2030. The key drivers of this industry include advancements in technology, the growing prevalence of chronic diseases, rising healthcare costs, and increasing consumer health awareness. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
The Canada Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $0.824 Bn in 2022 to $1.294 Bn by 2030, with a CAGR of 5.8% during the forecast period of 2022-2030. The key drivers of the Canadian congestive Heart Failure Therapeutics Market include the increasing prevalence of risk factors leading to CVS disorders, advancements in medical technology and intervention options, and supportive government schemes and reimbursement strategies. The Canada Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Johnson & Johnson, Apotex, Paladin Labs, Pharmascience, Sandoz, etc, among various others.
Canada Cancer Induced Bone Disease Therapeutics Market valued at $104 Mn in 2022, projected to reach $163 Mn by 2030 with a 5.8% CAGR. The key drivers of this industry include rising cancer incidence, increased research and development, and advancements in cancer diagnostics. The industry is primarily dominated by players such as Amgen, Pfizer, Merck, Eli Lilly, Novartis, Bayer, and Johnson & Johnson, among others.
Canada Car T-Cell Therapy Market valued at $232 Mn in 2022, projected to reach $393 Mn by 2030 with a 6.8% CAGR. The growing occurrence and prevalence of cancer worldwide, driven by factors like population aging, unhealthy lifestyles, and environmental influences, contribute to an expanding pool of patients who may potentially benefit from CAR T-Cell therapy, thereby expanding the market for this treatment. The top pharmaceutical entities presently operating in the market are Gilead Sciences (Kite Pharma), Novartis, Bristol Myers Squibb, Celgene, Johnson & Johnson, Cellectis, Atara Biotherapeutics, Adaptimmune Therapeutics, Poseida Therapeutics and UCAR-T.
The Canada Physiotherapy Equipment Market was valued at $1,672 Mn in 2023 and is predicted to grow at a CAGR of 7.2% from 2023 to 2030, to $2,720.19 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic diseases, expanding geriatric population, and advancements in technology. The key players in the industry are Medelco, Ortho Canada, Enraf-Nonius BV, and Body Best among others.
The Canada Dental Consumables Market was valued at $2704 Mn in 2023 and is projected to grow at a CAGR of 8.0% from 2023 to 2023, to $4634.2 Mn by 2030. The key drivers of this industry growing dental care needs, technological advancements, expanding dental infrastructure, increasing disposable incomes, public health initiatives, dental tourism, rising consumption of sugary and starchy foods, rise in unhealthy eating habits due to rising urbanization, changing living standards. The industry is primarily dominated by players such as Dentsply Sirona, 3M, Straumann Holding, Henry Schein, Patterson Companies among others.
Canada Cardiac Resynchronization Therapy Market valued at $384 Mn in 2022, projected to reach $567 Mn by 2030 with a 5% CAGR. The rising global prevalence of heart failure, driven by aging populations and lifestyle-related cardiovascular diseases, serves as a key growth driver for the Cardiac Resynchronization Therapy (CRT) market. Currently, leading pharmaceutical companies in this market include Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.